



HHS Public Access

Author manuscript

J Neurovirol. Author manuscript; available in PMC 2021 August 01.

Published in final edited form as:

J Neurovirol. 2020 August ; 26(4): 496–508. doi:10.1007/s13365-020-00846-z.

A candidate gene study of intermediate histopathological phenotypes in HIV-associated neurocognitive disorders

Andrew J. LEVINE, Ph.D.*,

Department of Neurology, David Geffen School of Medicine at the University of California, Los

Virawudh SOONTORNNIYOMKIJ, M.D.,

Department of Psychiatry, University of California San Diego School of Medicine

Eliezer MASLIAH, M.D.,

Departments of Neurosciences and Pathology, University of California San Diego School of Medicine

Janet S. SINSHEIMER, Ph.D.,

Departments of Human Genetics and Computational Biology, David Geffen School of Medicine at the University of California, Los Angeles

Department of Biostatistics, UCLA Fielding School of Public Health

Sarah S. JI, M.S.,

Department of Biostatistics, UCLA Fielding School of Public Health

Steve HORVATH, Ph.D.,

Department of Human Genetics, David Geffen School of Medicine at the University of California, Los Angeles

Department of Biostatistics, UCLA Fielding School of Public Health

Elyse J. SINGER, M.D.,

Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles

Asha KALLIANPUR, M.D.,M.P.H.,

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1>

*Corresponding Author: UCLA - Reed Neurological Research Center, 710 Westwood Plaza, Room 3-234, Los Angeles, CA 90095. Phone - 562-477-5963 Fax - 510-280-2993.

All authors contributed to the study conception, design, and/or execution. Andrew Levine and David Moore were involved in the initial study conception and design. Asha Kallianpur was involved in selecting genetic markers for the study. Data and specimen collection were performed or overseen by David Moore and Elyse Singer at their respective National NeuroAIDS Tissue Consortium sites. Tissue analysis was performed by Virawudh Soontornniyomkij and Eliezer Masliah. Data analysis was performed by Janet Sinsheimer, Sarah, Ji, Steve Horvath, and Andrew Levine. The first draft of the manuscript was written by Andrew Levine, David Moore, Virawudh Soontornniyomkij, Janet Sinsheimer, and Sarah Ji, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of a an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

None of the authors have reportable conflicts of interest.

Genomic Medicine, Medicine, & Pediatrics, Cleveland Clinic/Lerner Research Institute
Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University, Cleveland, OH

David J. MOORE, Ph.D.

Department of Psychiatry, University of California San Diego School of Medicine

Abstract

Background: HIV-associated neurocognitive disorders (HAND) describe a spectrum of neuropsychological impairment caused by HIV-1 infection. While the sequence of cellular and physiological events that lead to HAND remains obscure, it likely involves chronic neuroinflammation. Host genetic markers that increase risk for HAND have been reported, but replication of such studies is lacking, possibly due to inconsistent application of a behavioral phenotype across studies. In the current study, we used histopathologic phenotypes in order to validate putative risk alleles for HAND.

Setting: The National NeuroAIDS Tissue Consortium, a longitudinal study of the neurologic manifestations of HIV.

Methods: Data and specimens were obtained from 175 HIV-infected adults. After determining several potential covariates of neurocognitive functioning, we quantified levels of six histopathological markers in frontal lobe in association with neurocognitive functioning: SYP, MAP2, HLA-DR, Iba1, GFAP, and β -amyloid. We then determined alleles of 15 candidate genes for their associations with neurocognitive functioning and histopathological markers. Finally, we identified the most plausible causal pathway based on our data using a multi-stage linear regression-based mediation analysis approach.

Results: None of the genetic markers were associated with neurocognitive functioning. Of the histopathological markers, only MAP2 and SYP were associated with neurocognitive functioning; however, MAP2 and SYP did not vary as a function of genotype. Mediation analysis suggests a causal pathway in which presynaptic degeneration (SYP) leads to somatodendritic degeneration (MAP2) and ultimately neurocognitive impairment.

Conclusions: This study did not support the role of host genotype in the histopathology underlying HAND. The findings lend further support for synaptodendritic degeneration as the proximal underlying neuropathological substrate of HAND.

Keywords

HIV-associated neurocognitive disorder; genetic; histopathology; neuropathology; NeuroAIDS; synaptodendritic

INTRODUCTION

Pharmaceutical advances stemming from immunologic and genetic research have greatly improved and extended the lives of people living with HIV-1 (PLWH). Despite this, the prevalence of neurocognitive deficits in PLWH, collectively termed HIV-associated neurocognitive disorders (HAND), remains high (1, 2). Prior to the widespread use of

combination antiretroviral therapy (cART), neurocognitive syndromes due to HIV-1 infection were often severe and largely considered the manifestation of HIV encephalitis (3–13). However, HAND currently presents with milder symptoms in the vast majority of cART-treated cases (14, 15) and is not typically associated with HIV encephalitis (16). Instead, the neuropathogenesis of HAND is now believed to be largely the result of neurodegeneration driven by chronic neuroinflammation (5, 7, 13, 16).

Candidate gene studies have identified functional variants, largely within immune-related genes, that modify risk for HAND (as reviewed in (17, 18)). Such findings make sense biologically, supporting the role of inflammation in HAND pathogenesis. For example, some chemokines affect neuronal signaling with subsequent disturbance of glial and neuronal functions (19), while others serve to block the HIV-1 co-receptor, thus mitigating HIV-1 replication (20) and slowing disease progression (21, 22), as well as reducing macrophage activation and chemotaxis of monocytes and other cells into the brain (23, 24). In addition to immune-related genes, candidate gene studies have implicated dopaminergic dysregulation (17, 25–28), variation in mitochondrial function (29, 30), and cellular lipid and cholesterol transport in HAND pathogenesis, as recently reviewed in (31). However, very few candidate gene markers have been replicated in subsequent studies by independent groups. One likely reason for this is that the vast majority of these studies utilized behavioral phenotypes (e.g., HAND diagnosis or neurocognitive functioning), with little consistency between studies. Due to the inherent limitations of neurocognitive assessment (e.g., measurement error due to tests' psychometric properties and engagement by the examinee), coupled with the poor inter-rater agreement of what distinguishes HAND from other causes of neurocognitive impairment (32), a more fruitful strategy may be to focus on histopathological phenotypes.

Putative immunohistochemical markers of the neuropathological changes underlying HAND include synaptophysin (SYP) and microtubule-associated protein-2 (MAP2) (33), abnormal protein aggregates such as β -amyloid (34–38), and markers of microglial/macrophage activation, astroglial activation, and dysregulated cytokine expression (5–13). If previously identified genetic variants modify risk for HAND, it logically follows that those variants also modify the cellular and pathophysiological pathways that underlie HAND. Bridging the informational gap between genotypes and behavioral phenotypes in the context of HAND may provide important insights about pathogenesis. We recently reported results of an ambitious study that bridged genetic, histopathological, virologic, and neurocognitive data within subjects in order to understand which histopathological features and genetic variants were relevant to HAND pathogenesis (39). That study identified several genetic susceptibility loci that influenced histopathology and other disease parameters. Most notably, neurocognitive functioning was strongly correlated with levels of MAP2 and SYP in frontal cortex, both of which declined as plasma HIV-1 RNA viral load increased. This underscores the widely reported process by which HIV-1 replication-related events lead to synaptodendritic degeneration. Furthermore, an inverse relationship between SYP expression and β -amyloid plaque burden in frontal cortex suggests that HIV-1 replication in the brain may be a driver of the histopathological changes or, alternatively, an initiator of a causal chain of events involving neuroinflammation (reflected by ionized calcium-binding adapter molecule-1 (Iba1)) and dysfunctional protein clearance (reflected by β -amyloid plaque deposition). Downstream to these changes is synaptodendritic degeneration which is

the immediate histopathological substrate of HAND, although several factors likely modify this cascade (40–43) and the ultimate manifestation of HAND (31, 44–47).

In the current study, we expanded upon the previous findings (39). In the previous paper, we were unable to examine how demographic factors, HIV-1 disease variables, and host genotypes predicted MAP2 and SYP levels due to the low number of cases. In the current study, we first revisited this relationship by examining data from a larger sample of PLWH. Second, we assessed whether a variety of histopathological markers were associated with neurocognitive functioning among the larger sample. Third, we genotyped several additional genetic susceptibility loci and tested for association with the histopathological markers within frontal cortex. Finally, we examined the causal pathway between these histopathological markers and global neuropsychological functioning. Our goal was to exploit knowledge of functional polymorphisms to identify the relevant genes and histopathological markers involved in HAND pathogenesis.

METHODS

Biological specimens were obtained from the National NeuroAIDS Tissue Consortium (NNTC) (48). The NNTC is a longitudinal study of neuroAIDS in existence since 1998. Specimens and data used in the current study generally came from participants recruited because they had one or more diagnoses indicative of advanced HIV-1 disease, were at high risk of death, and agreed to participate in the study evaluations and to donate their organs for research purposes. Participants were typically evaluated every 6–12 months, undergoing comprehensive neurocognitive testing, psychiatric/substance use interview, and neuromedical evaluation. Upon death, brains were harvested for research purposes. Demographic and HIV-1 disease characteristics of individuals included in the current study are shown in Table 1.

For inclusion, all cases were required to be HIV-seropositive, 18 years or older, and diagnosed as either neurocognitively normal or with HAND within one year prior to death, per established research criteria (1, 49). Those determined to be neurocognitively impaired due to other causes were not included. All cases died well into the cART era (post-1996). Exclusion criteria were 1) pre- or post-mortem evidence of non-HIV related neurological diseases (e.g., stroke, neoplasm, multiple sclerosis, traumatic brain injury, and neurodegenerative illness) and 2) history or evidence of central nervous system (CNS) toxoplasmosis or progressive multifocal leukoencephalopathy. Comorbid medical conditions were in most cases self-reported by participants during the visits just prior to death, and were confirmed via chart review whenever possible. Sample characteristics are displayed in Table 1.

DNA Extraction and Genotyping

DNA extraction and genotyping methods are provided in the Supplemental Material. Table 2 displays the genes, specific reference SNP cluster ID numbers, and gene function.

Clinical Variables

Neurocognitive Functioning—Neuropsychological clinical ratings were determined for each case based on neurocognitive test scores obtained within one year of death. A global ability rating was derived from demographically corrected T-scores from a comprehensive neuropsychological battery, as previously described (32). Clinical ratings were assigned on a scale that ranged from 1 (above average) to 9 (severely impaired), with scores greater than or equal to 5 indicative of at least mild impairment. These were summarized as a Global Clinical Rating (GCR). Among PLWH, the GCR was associated with activities of daily living (50), HIV-1 disease variables (2), and synaptodendritic changes on brain histopathology (33).

HIV-1 Disease Measures—Peripheral blood was collected from living participants by venipuncture into EDTA and heparinized tubes prior to death and was assayed using the Roche Amplicor Assay for HIV-1 RNA viral load and by flow cytometry for CD4+ T-lymphocyte subsets. Plasma HIV-1 RNA viral load was measured at the last pre-mortem visit within one year of death. Plasma measures of viral load and CD4+ T-cell count were not available at the time of death because venipuncture cannot be performed after the heart has ceased beating due to intravascular blood coagulation. Duration of HIV-1 infection was based on self-reported date of infection and confirmed by chart review when possible.

Antiretroviral CNS Penetration or Effectiveness (CPE)—We employed the CPE, a score that is based on the pharmacologic characteristics of antiretroviral medications (51). The CPE of individual antiretroviral drugs is ranked from 1 (poorest) to 4 (best) based on the 2010 ranking system (52). The CPE score for each case was derived by adding ranks of all antiretroviral drugs within the regimen, which was reported at the time of neurocognitive testing. Higher scores indicated a regimen with increased penetration of the blood-brain barrier.

Alcohol and Substance Use—The Psychiatric Research Interview for Substance and Mental Disorders (PRISM) (53) or Composite International Diagnostic Interview (CIDI) (54) were used to ascertain lifetime substance use disorders. Both are structured diagnostic interviews that yield DSM-IV diagnoses. For the purposes of the current study, NNTC participants were classified with none, current, or past substance use disorder for the following drugs: cocaine, opioids, and methamphetamine. Alcohol use was similarly classified.

Immunohistochemistry and Histopathological Characterization

As described in (4, 55), brain tissue was harvested from deceased HIV-seropositive NNTC participants as soon as possible after death. Tissue blocks measuring 4 cm³ were taken from the right dorsolateral midfrontal cortex. The blocks were fixed overnight in 4% paraformaldehyde and cut at 40 μm thick with a Leica Vibratome (Vienna, Austria). Histopathological characterization was accomplished using previously described methods (4, 55) based on immunohistochemistry conducted on formalin-fixed paraffin-embedded sections. The mid-frontal gyrus was processed for the following markers: SYP (grey matter), MAP2 (grey matter), human leukocyte antigen-DR (HLA-DR, grey and white matter

separately), Iba1 (grey and white matter separately), glial fibrillary acidic protein (GFAP, grey and white matter separately), and β -amyloid (grey matter). Additional details of immunohistochemistry analysis and quantitative image analysis are in the Supplemental Material.

Statistical Analysis

Significance was assessed at a false discovery rate (FDR) of 0.05 (56).

All genetic loci except *MBL2* and *APOE* were treated as having a dominant acting risk allele. *MBL2* genotypes were treated as three categories (A/A, A/O, and O/O). To test the association of *APOE* $\epsilon 4$ and $\epsilon 2$ alleles with GCR, we modeled dominant main effects and an interaction between $\epsilon 4$ and $\epsilon 2$ in order to allow the inclusion of participants carrying the *APOE* $\epsilon 2/\epsilon 4$ genotype. Symbolically, this model was:

$$\text{GCR}_i = \alpha + \beta_{\epsilon 4} I_{\{i, \epsilon 4/\epsilon 4, \epsilon 4/\epsilon 3, \epsilon 4/\epsilon 2\}} + \beta_{\epsilon 2} I_{\{i, \epsilon 2/\epsilon 2, \epsilon 2/\epsilon 3, \epsilon 4/\epsilon 2\}} + \gamma_{\epsilon 4 \epsilon 2} I_{\{i, \epsilon 4/\epsilon 4, \epsilon 4/\epsilon 3, \epsilon 4/\epsilon 2\}} I_{\{i, \epsilon 2/\epsilon 2, \epsilon 2/\epsilon 3, \epsilon 4/\epsilon 2\}} + \epsilon_i$$

where $I_{\{\epsilon 4/\epsilon 4, \epsilon 4/\epsilon 3, \epsilon 4/\epsilon 2\}} = 1$ if individual i 's genotype was $\epsilon 4/\epsilon 4$, $\epsilon 4/\epsilon 3$, or $\epsilon 4/\epsilon 2$ and = 0 otherwise, $I_{\{\epsilon 2/\epsilon 2, \epsilon 2/\epsilon 3, \epsilon 4/\epsilon 2\}} = 1$ if individual i 's genotype was $\epsilon 2/\epsilon 2$, $\epsilon 2/\epsilon 3$, or $\epsilon 4/\epsilon 2$ and = 0 otherwise, and ϵ_i was the residual error. If the evidence for interaction was not significant, we reduced the model to: $\text{GCR}_i = \alpha + \beta_{\epsilon 4} I_{\{i, \epsilon 4/\epsilon 4, \epsilon 4/\epsilon 3, \epsilon 4/\epsilon 2\}} + \beta_{\epsilon 2} I_{\{i, \epsilon 2/\epsilon 2, \epsilon 2/\epsilon 3, \epsilon 4/\epsilon 2\}} + \epsilon_i$

To test potential causal pathways involving histopathological markers, we used a multi-stage linear regression-based mediation analysis approach (57, 58). The evidence for a particular pathway was provided by the proportion of the effect of a predictor that could be explained by the effect of a mediator (the proportion mediated). The proportion mediated was determined by conducting two linear regressions: 1) regressing the mediator on the predictor and 2) regressing the outcome on the mediator and the predictor. Additional covariates could be included in both regressions if desired.

RESULTS

We first determined if potential confounders were associated with GCR (Table 3), including age at death, sex (female or reference group male), duration of HIV-1 infection, log₁₀ plasma HIV-1 RNA viral load (herein referred to as viral load), NNTC site (reference group site 1), CD4+ T-cell count, CPE score, self-reported race/ethnicity (African American, Hispanic, Asian/Native Alaskan, or reference group Caucasian), alcohol use (current, past, or reference group none), or drug use (current, past, or reference group none). Only viral load was associated with GCR using a significance threshold of 0.05. Because the inclusion of race/ethnicity could reduce the effects of population stratification that confounded genetic association analyses, we included race/ethnicity in our subsequent analyses despite lack of statistical significance.

We next tested each of the histopathological markers' association with GCR, controlling for the effects of race/ethnicity and viral load (Table 4). Only MAP2 and SYP were associated

with GCR at an FDR of 0.05. We then determined whether the potential confounders were associated with MAP2 or SYP. The viral load was significantly associated with SYP. None of the potential confounder variables were associated with MAP2 (Table 3).

Association of Genotype with GCR, SYP, and MAP2

We next determined candidate genetic markers' associations with GCR, SYP, or MAP2. Because genetic associations could be confounded by population stratification, we included race/ethnicity as a covariate in all subsequent analyses despite its lack of statistical significance. When using a nominal per test *p*-value cutoff of 0.05, *HFE*, *HEPH* and *MBL2* were associated with GCR, *NFE2L2* and *CCR2* were associated with SYP, and *NFE2L2* and *HCP5* were associated with MAP2. However, none of the genetic markers were significantly associated with GCR, SYP or MAP2 at an FDR of 0.05 (Table 5). Thus, when further testing for the association of MAP2 and SYP with GCR, we did not include genetic markers.

Mediation Analysis

When both MAP2 and SYP were simultaneously included as predictors, MAP2, but not SYP, was associated with GCR (Table 6). This suggests the relationship of SYP and GCR is mediated by MAP2; however, there was strong collinearity between MAP2 and SYP. To test this potential pathway, we used mediation analyses to determine the most plausible pathway that could explain the observed association of SYP, MAP2 and GCR. We assumed that GCR would not influence SYP or MAP2; therefore, we limited our analyses to four possible pathways: 1) the effect of SYP on GCR was mediated through MAP2 (SYP → MAP2 → GCR); 2) the effect of MAP2 on GCR was mediated through SYP (MAP2 → SYP → GCR); 3) neither SYP nor MAP2 was a mediator of the other; and 4) a more complex pathway in which both MAP2 and SYP mediated the effects of each other, possibly due to unmeasured variables. If pathway 1 (SYP → MAP2 → GCR) was the predominant pathway, we would expect the mediation effects to be significant for this pathway and not for pathway 2 (MAP2 → SYP → GCR). If pathway 2 was the predominant pathway, the mediation effects would be significant for this pathway and not for pathway 1. If neither SYP nor MAP2 mediated, neither analysis would be statistically significant. If both SYP and MAP2 had direct and mediated effects, both analyses would be expected to be statistically significant. Based on the mediation analyses, the statistical support for pathway 1 (Figure 1) was much stronger than that for pathway 2 (Figure 2). Therefore, these results were most consistent with the SYP → MAP2 → GCR causal pathway.

DISCUSSION

In the current study, we took several steps to address the question of whether or not host genotype affected the histopathological factors that underlay the neurocognitive dysfunction common to PLWH. The first step involved determining if the quantitative measure of neurocognitive functioning (i.e., GCR) was associated with virologic, demographic, mood, CNS penetration of antiretroviral medication, and/or substance use factors. In this sample, only plasma HIV-1 RNA viral load was significantly associated with GCR. This finding might be somewhat unexpected considering that recent studies did not find viral load to be associated with cognitive functioning, at least in the current era of widespread cART use

(59). However, the NNTC cohort is composed of individuals with more advanced illness, in which viral load was likely higher and cognitive functioning poorer than in clinical cohorts of living PLWH in general. Furthermore, the higher viral load might reflect poor medication adherence and health in general, which suggests that other medical factors not captured in the current analysis (e.g., metabolic syndrome and comorbid medical illnesses) may be contributing. The lack of association between demographics and GCR may be due to the use of normative data when interpreting neurocognitive test scores. That is, standardized scores were derived using age, education, gender, and/or ethnicity stratified normative data. Neither current nor past substance or alcohol use disorder was associated with GCR, despite our focus on the most neurotoxic drugs (cocaine, methamphetamine, and opioids). This is somewhat surprising considering that the majority of past studies have reported an increased risk of neurocognitive impairment associated with substance use (60–63). One possible explanation is that the relatively advanced disease stage of our sample, with concomitant higher rates of severe cognitive impairment (i.e., HIV-associated dementia), might simply overshadow the damaging effects of alcohol or substance use. Finally, as a group our sample was neurocognitively impaired based on the average GCR. The reason for this impairment may not have been captured by our study due to incomplete data collection, as mentioned above. Among those important variables not captured were comorbid medical conditions, which in more recent studies appeared to be among the greatest predictors of neurocognitive impairment (44, 64–67). As such, the documented adverse effects of the recreational drugs included in our analyses, as well perhaps of depression, may have been overshadowed by factors that were not measured.

The second step involved determining which histopathological markers were associated with GCR. Only MAP2 and SYP were found to be significant predictors of global cognitive functioning. This finding is consistent with our earlier study (39), as well as other studies, many of which included samples from the NNTC (33, 68, 69). There are several mechanisms through which HIV-1 may affect synaptodendritic functioning, including direct actions via envelope protein gp120 and transactivator of transcription (tat) protein, as reviewed in (70). Furthermore, our inclusion of potential confounding variables found to be significant in the initial step of our analyses revealed that plasma HIV-1 RNA viral load was significantly associated with SYP, but not with MAP2.

In the third step, we tested for associations of each candidate genetic marker with GCR, SYP, and MAP2, controlling for plasma HIV-1 RNA viral load and race/ethnicity. We expected to discover some associations, based on our previous finding (39). However, there were no significantly associated genetic markers with any of the outcomes after correcting for multiple comparisons using an FDR of 0.05. Therefore, despite the increase in sample size from the previous study, we found no statistically significant association of these outcomes with the genetic markers, suggesting that these genetic pathways are not major determinants of neurocognitive dysfunction or neurodegeneration among PLWH with advanced disease. Such findings further underscore the likely lack of consistently significant genetic influence on neurobehavioral outcomes in PLWH, as reviewed in (17, 18).

The final step of our study was to apply mediation analysis to examine potential causal pathways relating SYP, MAP2, and GCR. This step was taken to determine if the effect of

MAP2 on GCR was mediated through SYP, or if the effect of SYP on GCR was mediated through MAP2. As the directed pathway of MAP2 to SYP to GCR did not show any significant evidence and the directed pathway of SYP to MAP2 to GCR was significant, the most plausible causal pathway is that MAP2 mediates the effect of SYP on GCR. Coupled with the findings from earlier steps, an overall model emerges in which elevated plasma HIV-1 RNA viral load results in presynaptic degeneration (as indicated by SYP levels), which in turn leads to somatodendritic degeneration (as indicated by MAP2 levels) and ultimately neurocognitive dysfunction. However, even if presynaptic degeneration is a downstream effect of more active systemic viral replication, it is almost certain that additional intermediary factors are involved, such as changes in neurogranin and calmodulin (40), cathepsin B and serum amyloid p component (41), E2F transcription factor-3 (42), and *BCL11B*-encoded protein (43), to name just a few. Importantly, this putative multicomponent sequence of events leading to neurocognitive dysfunction in PLWH is just one of a list of several other causes, a list that includes medical comorbidities (44, 45), low-grade systemic chronic inflammation (31), and antiretroviral medication toxicity (46, 47).

The current study had several limitations. Perhaps most important was the absence of key variables in our analysis, including those mentioned in the immediately preceding paragraph (e.g., medical comorbidities), as well as brain HIV-1 viral load, CD163, and germane medical comorbidities. Additionally, the generalizability of the findings to the current cART era is limited, as the NNTC cases typically have more advanced illness and comorbidities than the vast majority of PLWH, at least within the United States (48). This is best demonstrated by the relatively high rate of HIV-associated dementia (29%) and HIV encephalitis (9%) in our sample. Our use of plasma HIV-1 RNA viral load rather than the brain- or CSF-derived viral load also limits the interpretability, as these two measures are not strongly correlated (71, 72). Finally, while our study may be among the largest genetic-histopathological studies of HIV-related neurocognitive impairment, the statistical power was nevertheless limited by the sample size.

In conclusion, while our results affirmed the role of synaptodendritic degeneration in HIV-related neurocognitive impairment, we did not find definitive evidence of a host genetic influence on these histopathological markers among individuals with advanced HIV-1 disease. Our study adds to the existing literature of genetic association studies of HAND, which have focused on behavioral rather than histopathological phenotypes. Our findings do suggest that presynaptic degeneration precedes somatodendritic degeneration in the lead up to neurocognitive impairment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This publication was made possible from NIH funding (R01MH096648 - Levine & Moore); along with shared resources from NIH funding through the NIMH and NINDS to the National NeuroAIDS Tissue Consortium (NNTC), which is supported through the following grants: Manhattan HIV Brain Bank - U24MH100931; Texas NeuroAIDS Research Center - U24MH100930; National Neurological AIDS Bank - U24MH100929; California NeuroAIDS Tissue Network - U24MH100928; Data Coordinating Center - U24MH100925.

The contents in this paper are the responsibility of the authors and do not necessarily represent the official view of the NNTC or NIH.

REFERENCES

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69(18):1789–99 [PubMed: 17914061]
2. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*. 2011;17(1):3–16. doi: 10.1007/s13365-010-0006-1. [PubMed: 21174240]
3. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. *Neurology*. 1993;43(11):2245–52. [PubMed: 8232937]
4. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey CL, Cherner M, Ellis RJ, Achim CL, Marcotte TD, Heaton RK, Grant I. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. *AIDS*. 2006;20(6):879–87. doi: 10.1097/01.aids.0000218552.69834.00 [PubMed: 16549972]
5. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. *Ann Neurol*. 1995;38(5):755–62. doi: 10.1002/ana.410380510. [PubMed: 7486867]
6. Bell JE, Brettle RP, Chiswick A, Simmonds P. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. *Brain*. 1998;121 (Pt 11):2043–52. [PubMed: 9827765]
7. Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. *J Leukoc Biol*. 2003;74(5):691–701. [PubMed: 14595004]
8. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. *Neurotox Res*. 2005;8(1–2):51–61. [PubMed: 16260385]
9. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-Beck J, Navia B. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. *J Neurovirol*. 2011;17(1):63–9. doi: 10.1007/s13365-010-0013-2. [PubMed: 21246320]
10. Boven LA, Middel J, Breij EC, Schotte D, Verhoef J, Soderland C, Nottet HS. Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines. *J Neurovirol*. 2000;6(5):382–9. [PubMed: 11031691]
11. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. *Proc Natl Acad Sci U S A*. 1998;95(6):3117–21. [PubMed: 9501225]
12. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. *J Neurosci*. 2006;26(4):1098–106. doi: 26/4/1098 [pii] 10.1523/JNEUROSCI.3863–05.2006. [PubMed: 16436595]
13. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. *Neuron*. 2009;64(1):133–45. doi: S0896–6273(09)00753–3 [pii] 10.1016/j.neuron.2009.09.042. [PubMed: 19840555]
14. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. *Lancet Neurol*. 2005;4(9):543–55. doi: S1474–4422(05)70165–4 [pii] 10.1016/S1474–4422(05)70165–4. [PubMed: 16109361]


15. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, for the C, Groups H. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol.* doi: 10.1007/s13365-010-0006-1.
16. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, Gelman B, Morgello S, Singer E, Grant I, Masliah E, National Neuro ATC. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. *J Neurovirol.* 2009;15(5–6):360–70. doi: 10.3109/13550280903131915. [PubMed: 20175693]
17. Levine AJ, Panos SE, Horvath S. Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder. *J Acquir Immune Defic Syndr.* 2014;65(4):481–503. doi: 10.1097/QAI.0000000000000069. [PubMed: 24583618]
18. Kallianpur AR, Levine AJ. Host Genetic Factors Predisposing to HIV-Associated Neurocognitive Disorder. *Curr HIV/AIDS Rep.* 2014. doi: 10.1007/s11904-014-0222-z.
19. Zheng J, Thylin MR, Persidsky Y, Williams CE, Cotter RL, Zink W, Ryan L, Ghorpade A, Lewis K, Gendelman HE. HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. *Neurotox Res.* 2001;3(5):461–84. [PubMed: 14715459]
20. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. The C-X-C chemokine IP-10 stimulates HIV-1 replication. *Virology.* 2003;307(1):122–34. doi: S0042682202000454 [pii]. [PubMed: 12667820]
21. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, Anderson SA, Walter EA, Stephan KT, Hammer MF, Mangano A, Sen L, Clark RA, Ahuja SS, Dolan MJ, Ahuja SK. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. *Proc Natl Acad Sci U S A.* 2001;98(9):5199–204. [PubMed: 11320252]
22. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. *Science.* 2005;307(5714):1434–40. doi: 1101160 [pii] 10.1126/science.1101160. [PubMed: 15637236]
23. Kaul M, Lipton SA. Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin. *Neurotox Res.* 2005;8(1–2):167–86. [PubMed: 16260394]
24. Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. *J Immunol.* 1999;163(5):2953–9. [PubMed: 10453044]
25. Kumar AM, Fernandez J, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. *J Neurovirol.* 2009;1–18. [PubMed: 19462266]
26. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. *J Neurovirol.* 2011;17(1):26–40. doi: 10.1007/s13365-010-0003-4. [PubMed: 21165787]
27. Levine AJ, Sinsheimer JS, Bilder R, Shapshak P, Singer EJ. Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults. *J Clin Exp Neuropsychol.* 2012;34(1):78–91. doi: 10.1080/13803395.2011.623118. [PubMed: 22082040]
28. Levine AJ, Reynolds S, Cox C, Miller EN, Sinsheimer JS, Becker JT, Martin E, Sacktor N, Neuropsychology Working Group of the Multicenter ACS. The longitudinal and interactive effects of HIV status, stimulant use, and host genotype upon neurocognitive functioning. *J Neurovirol.* 2014;20(3):243–57. doi: 10.1007/s13365-014-0241-y. [PubMed: 24737013]
29. Samuels DC, Kallianpur AR, Ellis RJ, Bush WS, Letendre S, Franklin D, Grant I, Hulgán T. European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers

- of Inflammation in HIV Infection. *Pathog Immun*. 2016;1(2):330–51. doi: 10.20411/pai.v1i2.156. [PubMed: 28317034]
30. Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR, Group C. Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. *Clin Infect Dis*. 2015;61(9):1476–84. doi: 10.1093/cid/civ527. [PubMed: 26129753]
 31. Geffin R, McCarthy M. Aging and Apolipoprotein E in HIV Infection. *J Neurovirol*. 2018. doi: 10.1007/s13365-018-0660-2.
 32. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Cherner M, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. *J Clin Exp Neuropsychol*. 2004;26(6):759–78. [PubMed: 15370374]
 33. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey CL, Cherner M, Ellis RJ, Achim CL, Marcotte RD, Heaton RK, Grant I. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. *Aids*. 2006;20(6):879–87. [PubMed: 16549972]
 34. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. *J Neuroimmune Pharmacol*. 2009;4(2):190–9. doi: 10.1007/s11481-009-9152-8. [PubMed: 19288297]
 35. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. *AIDS*. 2005;19(2):127–35. doi: 00002030–200501280-00004 [pii]. [PubMed: 15668537]
 36. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. *AIDS*. 2005;19(4):407–11. doi: 00002030–200503040-00006 [pii]. [PubMed: 15750394]
 37. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. *J Neurol Neurosurg Psychiatry*. 1998;65(1):29–33. [PubMed: 9667557]
 38. Soontornniyomkij V, Moore DJ, Gouaux B, Soontornniyomkij B, Tatro ET, Umlauf A, Masliah E, Levine AJ, Singer EJ, Vinters HV, Gelman BB, Morgello S, Cherner M, Grant I, Achim CL. Cerebral beta-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE epsilon4 carriers. *AIDS*. 2012. doi: 10.1097/QAD.0b013e32835a117c.
 39. Levine AJ, Soontornniyomkij V, Achim CL, Masliah E, Gelman BB, Sinsheimer JS, Singer EJ, Moore DJ. Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. *J Neurovirol*. 2015. doi: 10.1007/s13365-015-0410-7.
 40. Guha D, Wagner MCE, Ayyavoo V. Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. *J Neuroinflammation*. 2018;15(1):126. doi: 10.1186/s12974-018-1160-2. [PubMed: 29703241]
 41. Cantres-Rosario YM, Ortiz-Rodriguez SC, Santos-Figueroa AG, Plaud M, Negron K, Cotto B, Langford D, Melendez LM. HIV Infection Induces Extracellular Cathepsin B Uptake and Damage to Neurons. *Sci Rep*. 2019;9(1):8006. doi: 10.1038/s41598-019-44463-1. [PubMed: 31142756]
 42. Santerre M, Bagashev A, Gorecki L, Lysek KZ, Wang Y, Shrestha J, Del Carpio-Cano F, Mukerjee R, Sawaya BE. HIV-1 Tat protein promotes neuronal dysregulation by inhibiting E2F transcription factor 3 (E2F3). *J Biol Chem*. 2019;294(10):3618–33. doi: 10.1074/jbc.RA118.003744. [PubMed: 30591585]
 43. Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S, Ellis R, Cherner M, Grant I, Masliah E. Molecular and pathologic insights from latent HIV-1 infection in the human brain. *Neurology*. 2013;80(15):1415–23. doi: 10.1212/WNL.0b013e31828c2e9e. [PubMed: 23486877]
 44. Saloner R, Heaton RK, Campbell LM, Chen A, Franklin D Jr., Ellis RJ, Collier AC, Marra C, Clifford DB, Gelman B, Sacktor N, Morgello S, McCutchan JA, Letendre S, Grant I, Fennema-Notestine C, Group CS. Effects of comorbidity burden and Age on brain integrity in HIV. *AIDS*. 2019. doi: 10.1097/QAD.0000000000002192.
 45. Yu B, Pasipanodya E, Montoya JL, Moore RC, Gianella S, McCutchan A, Ellis R, Heaton RK, Jeste DV, Moore DJ, Marquine MJ. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection. *J Acquir Immune Defic Syndr*. 2019;81(1):95–101. doi: 10.1097/QAI.0000000000001964. [PubMed: 30664077]

46. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. *J Pharmacol Exp Ther*. 2012;343(3):696–703. doi: 10.1124/jpet.112.195701. [PubMed: 22984227]
47. Gannon PJ, Akay-Espinoza C, Yee AC, Briand LA, Erickson MA, Gelman BB, Gao Y, Haughey NJ, Zink MC, Clements JE, Kim NS, Van De Walle G, Jensen BK, Vassar R, Pierce RC, Gill AJ, Kolson DL, Diehl JA, Mankowski JL, Jordan-Sciutto KL. HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via beta-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. *Am J Pathol*. 2017;187(1):91–109. doi: 10.1016/j.ajpath.2016.09.006. [PubMed: 27993242]
48. Morgello S, Gelman BB, Kozlowski PB, Vinters HV, Masliah E, Cornford M, Cavert W, Marra C, Grant I, Singer EJ. The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. *Neuropathol Appl Neurobiol*. 2001;27(4):326–35. [PubMed: 11532163]
49. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. *Neurology*. 1996;47(5):1247–53. [PubMed: 8909438]
50. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I. The impact of HIV-associated neuropsychological impairment on everyday functioning. *J Int Neuropsychol Soc*. 2004;10(3):317–31. doi: 10.1017/S1355617704102130 [PubMed: 15147590]
51. Letendre S Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. *Topics in antiviral medicine*. 2011;19(4):137–42. [PubMed: 22156215]
52. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. *Topics in HIV medicine : a publication of the International AIDS Society, USA*. 2010;18(2):45–55.
53. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. *Am J Psychiatry*. 1996;153(9):1195–201. [PubMed: 8780425]
54. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry*. 1988;45(12):1069–77. [PubMed: 2848472]
55. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. *Ann Neurol*. 1997;42(6):963–72. doi: 10.1002/ana.410420618. [PubMed: 9403489]
56. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Royal Stat Soc Ser B*. 1995;57:200–89.
57. MacKinnon D *Introduction to Statistical Mediation Analysis*. New York: Routledge; 2008.
58. Tingley DY, Tepperi; Hirose, Kentaro ; Keele, Luke; Imai, Kosuke mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software*. 2014;59(5):1–38. [PubMed: 26917999]
59. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. *The Lancet infectious diseases*. 2013;13(11):976–86. doi: 10.1016/S1473-3099(13)70269-X. [PubMed: 24156898]
60. Martin E, Keutmann MK, Fogel JS, Maki PM, Gonzalez R, Vassileva J, Rubin LH, Hardy D. Verbal and spatial working memory among drug-using HIV-infected men and women. *J Neurovirol*. 2018;24(4):488–97. doi: 10.1007/s13365-018-0639-z. [PubMed: 29687402]
61. Thaler NS, Sayegh P, Kim MS, Castellon SA, Hinkin CH. Interactive effects of neurocognitive impairment and substance use on antiretroviral non-adherence in HIV disease. *Arch Clin Neuropsychol*. 2015;30(2):114–21. doi: 10.1093/arclin/acu092. [PubMed: 25589442]
62. Persidsky Y, Ho W, Ramirez SH, Potula R, Abood ME, Unterwald E, Tuma R. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. *Brain Behav Immun*. 2011;25 Suppl 1:S61–70. doi: 10.1016/j.bbi.2011.03.001. [PubMed: 21397004]

63. Meyer VJ, Rubin LH, Martin E, Weber KM, Cohen MH, Golub ET, Valcour V, Young MA, Crystal H, Anastos K, Aouizerat BE, Milam J, Maki PM. HIV and recent illicit drug use interact to affect verbal memory in women. *J Acquir Immune Defic Syndr*. 2013;63(1):67–76. doi: 10.1097/QAI.0b013e318289565c. [PubMed: 23392462]
64. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. *Neurology*. 2016;86(4):334–40. doi: 10.1212/WNL.0000000000002277. [PubMed: 26718568]
65. Lake JE, Popov M, Post WS, Palella FJ, Sacktor N, Miller EN, Brown TT, Becker JT. Visceral fat is associated with brain structure independent of human immunodeficiency virus infection status. *J Neurovirol*. 2017;23(3):385–93. doi: 10.1007/s13365-016-0507-7. [PubMed: 27981440]
66. Wu M, Fatukasi O, Yang S, Alger J, Barker PB, Hetherington H, Kim T, Levine A, Martin E, Munro CA, Parrish T, Ragin A, Sacktor N, Seaberg E, Becker JT, Neuropsychology Working Group of the Multicenter ACS. HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition. *AIDS*. 2018;32(13):1803–10. doi: 10.1097/QAD.0000000000001891. [PubMed: 29794829]
67. Vance DE, Rubin LH, Valcour V, Waldrop-Valverde D, Maki PM. Aging and Neurocognitive Functioning in HIV-Infected Women: a Review of the Literature Involving the Women's Interagency HIV Study. *Curr HIV/AIDS Rep*. 2016;13(6):399–411. doi: 10.1007/s11904-016-0340-x. [PubMed: 27730446]
68. Bryant AK, Moore DJ, Burdo TH, Lakritz JR, Gouaux B, Soontornniyomkij V, Achim CL, Masliah E, Grant I, Levine AJ, Ellis RJ. Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. *AIDS*. 2017;31(7):973–9. doi: 10.1097/QAD.0000000000001425. [PubMed: 28244955]
69. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. *Lab Invest*. 1992;66(3):285–91. [PubMed: 1538584]
70. Wenzel ED, Avdoshina V, Mocchetti I. HIV-associated neurodegeneration: exploitation of the neuronal cytoskeleton. *J Neurovirol*. 2019;25(3):301–12. doi: 10.1007/s13365-019-00737-y. [PubMed: 30850975]
71. Gelman BB, Lisinicchia JG, Morgello S, Masliah E, Commins D, Achim CL, Fox HS, Kolson DL, Grant I, Singer E, Yiannoutsos CT, Sherman S, Gensler G, Moore DJ, Chen T, Soukup VM. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. *J Acquir Immune Defic Syndr*. 2013;62(5):487–95. doi: 10.1097/QAI.0b013e31827f1bdb. [PubMed: 23242157]
72. Bavaro DF, Calamo A, Lepore L, Fabrizio C, Saracino A, Angarano G, Monno L. Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood-brain barrier damage. *Infection*. 2019;47(3):441–6. doi: 10.1007/s15010-019-01268-8. [PubMed: 30649685]

SYP → MAP2 → GCR (MAP2 mediating SYP effect on GCR)




	Estimate	2.5%	97.5%	<i>p</i> value ^a
ACME	-0.083	-0.169	-0.008	0.032
ADE	-0.069	-0.194	0.053	0.282
Total effect	-0.152	-0.249	-0.050	0.004
Proportion mediated	0.547	0.045	1.832	0.036

Figure 1: Mediation analysis results for the model MAP2 mediating the effect of SYP on GCR. The model includes log10 plasma HIV-1 RNA viral load and race/ethnicity as covariates. Estimates for the average causal mediation effect (ACME), the average direct effect (ADE), and the total effect are denoted as closed circles, and the 95% confidence intervals (CI) are denoted as horizontal lines. Effects significant at a *p* value less than 0.05 do not cross the hatched vertical line at zero. The ACME *p* value = 0.032, the ADE *p* value = 0.282, and the total effect *p* value = 0.004. The proportion mediated = 0.547 (95% CI = 0.045, 1.832; *p* value = 0.036), supporting the hypothesis that MAP2 mediates the effect of SYP on GCR.

^a Controlling for log10 plasma HIV-1 RNA viral load and race/ethnicity

MAP2 → SYP → GCR (SYP mediating MAP2 effect on GCR)



	Estimate			<i>p</i> value ^a
	e	2.5%	97.5%	
ACME	-0.041	-0.125	0.036	0.296
ADE	-0.148	-0.276	-0.011	0.030
Total effect	-0.189	-0.291	-0.076	0.002
Proportion	0.212	-0.196	0.871	0.294

mediated

Figure 2: Mediation analysis results for the model SYP mediating the effect of MAP2 on GCR. The model includes log10 plasma HIV-1 RNA viral load and race/ethnicity as covariates. Estimates for the average causal mediation effect (ACME), the average direct effect (ADE), and the total effect are denoted as closed circles, and the 95% confidence intervals (CI) are denoted as horizontal lines. Effects significant at a *p* value less than 0.05 do not cross the hatched vertical line at zero. The ACME *p* value = 0.296, the ADE *p* value = 0.030, and the total effect *p* value = 0.002. The proportion mediated = 0.212 (95% CI = -0.196, 0.871; *p* value = 0.294), indicating a lack of support for the hypothesis that SYP mediates the effect of MAP2 on GCR.

^a Controlling for log₁₀ plasma HIV-1 RNA viral load and race/ethnicity

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1:

Sample characteristics

Age at death	47.4 years ^a (SD = 9.2)
Length of HIV infection	12 years (SD = 6.4)
CD4+ T-cell count	122 (SD = 168)
Median plasma HIV-1 RNA viral load	15406 copies/mL
CPE	8.96 (SD = 4.08)
Global clinical rating	5.31 (SD = 1.87)
	Percent ^b of sample (<i>n</i>)
Detectable (>50 copies/mL) plasma HIV-1 RNA viral load	84% (30)
Male	81.4% (162)
Race/ethnicity	
Caucasian	50.8% (100)
African American	24.9% (49)
Hispanic	22.3% (44)
Asian/Native Alaskan	2% (4)
Major depression	
Current	23.4% (32)
Past	16.8% (23)
Substance use disorder	
Current	20.3% (31)
Past	29.4% (45)
Alcohol use disorder	
Current	9% (14)
Past	26% (40)
HIV encephalitis	9.2% (16)
HAND	74.2% (135)
ANI	14.2% (26)
MND	31% (56)
HAD	29% (53)

SD standard deviation, *CPE* central nervous system penetration or effectiveness, *ANI* asymptomatic neurocognitive impairment, *MND* mild neurocognitive disorder, *HAD* HIV-associated dementia

^aValues presented as means unless otherwise indicated

^bPercentages are the proportion of those with available data

Table 2:

Candidate genes and their protein's primary function

Gene	Full name	Reference SNP cluster ID	Protein function
<i>IL6</i>	Interleukin 6	rs1800796	Pro-inflammatory cytokine
<i>CCL3</i>	C-C motif chemokine ligand 3	rs1719134	Chemokine involved in recruitment and activation of granulocytes
<i>HCP5</i>	HLA complex P5	rs2395029	A human endogenous retrovirus. Variants confer protection against AIDS
<i>CX3CR1</i>	C-X3-C motif chemokine receptor 1	rs3732379	Chemokine involved in adhesion and migration of leukocytes
<i>HFE</i>	Homeostatic iron regulator	rs1799945	Regulates circulating iron uptake via regulating interaction between transferrin receptor and transferrin
<i>NFE2L2</i>	Nuclear factor, erythroid 2 like 2	rs6706649	Transcription factor that regulates expression of antioxidant proteins in response to injury and inflammation
<i>CXCL12</i>	C-X-C motif chemokine ligand 12	rs1801157	Chemokine that activates leukocyte migration in CNS as part of inflammatory activation
<i>CCR2</i>	C-C motif chemokine receptor 2	rs1799864	Chemokine that mediates monocyte chemotaxis
<i>BDNF</i>	Brain derived neurotrophic factor	rs6265	Supports cell survival in CNS
<i>HEPH</i>	Hephaestin	rs1264212	Involved in metabolism and homeostasis of iron
<i>TNF</i>	Tumor necrosis factor	rs1800629	Pro-inflammatory cytokine
<i>CD33</i>	CD33 molecule (SIGLEC3)	rs3865444	Involved in inhibition of phagocytosis within cells
<i>CCL2</i>	C-C motif chemokine ligand 2	rs1024611	Pro-inflammatory cytokine
<i>MBL2</i>	Mannose binding lectin 2	rs1800450 rs1800451 rs5030737	Involved in innate immune response
<i>APOE</i>	Apolipoprotein E	rs429358 rs7412	Involved in lipid transport and metabolism

SNP single nucleotide polymorphism, *CNS* central nervous system

Table 3:
Potential confounding covariates of GCR, SYP, and MAP2

Covariate ^a	GCR			SYP			MAP2		
	Estimate	<i>p</i> value	<i>n</i>	Estimate	<i>p</i> value	<i>n</i>	Estimate	<i>p</i> value	<i>n</i>
Age at death	-0.022	0.156	175	0.005	0.915	102	0.007	0.875	102
Sex: Female	-0.429	0.227	175	-0.905	0.404	102	-0.316	0.763	102
NNTC site ^b :									
Site 2	0.596	0.148 ^a	175	NA	NA	NA	NA	NA	NA
Site 3	0.890			-0.123	0.880	102	-0.244	0.757	102
Site 4	0.427			NA	NA	NA	NA	NA	NA
Duration of HIV infection	-0.043	0.051	170	-0.006	0.919	98	-0.017	0.775	98
Log10 plasma HIV-1 RNA viral load	0.272	0.004	169	-0.600	0.040	95	-0.442	0.119	95
CD4+ T-cell count	-0.002	0.069	169	0.004	0.104	97	0.003	0.240	97
CPE	0.061	0.131	145	0.011	0.906	83	0.118	0.194	83
Race/ethnicity ^c :									
African American	-0.498	0.148 ^a	173	1.331	0.201	100	0.607	0.543	100
Hispanic	0.235	-	-	0.101	-	-	0.296	-	-
Asian/Native	0.969	-	173	-1.074	-	-	0.957	-	-
Alaskan									
Alcohol use:									
Current	0.58	0.271 ^a	151	2.71	0.133 ^a	71	0.155	0.930 ^a	71
Past	0.416	-	-	-1.376	-	-	-1.023	-	-
Drug use:									
Current	0.273	0.493 ^a	150	0.239	0.870 ^a	70	-0.528	0.704 ^a	70
Past	0.462	-	-	-0.507	-	-	-0.574	-	-

GCR global clinical rating, SYP synaptophysin, MAP2 microtubule-associated protein-2, NNTC National NeuroAIDS Tissue Consortium, CPE central nervous system penetration or effectiveness, NA not applicable

^aOmnibus *p* value

^bSite 1 as the reference site

^cCaucasian as the reference group

Table 4:

Histopathological marker associations with GCR controlling for race/ethnicity and plasma HIV-1 RNA viral load

	Effect size	<i>p</i> value ^a	<i>n</i>
Iba1 grey matter	-0.0176	0.2259	161
Iba1 white matter	-0.0234	0.0499	161
HLA-DR grey matter	0.0227	0.7310	160
HLA-DR white matter	0.0224	0.4039	160
GFAP grey matter	0.3357	0.1133	161
GFAP white matter	-0.1112	0.5873	161
β-amyloid grey matter	0.3496	0.1299	161
MAP2 grey matter	-0.1889	0.0003	82
SYP grey matter	-0.1518	0.0031	82

Iba1 ionized calcium-binding adapter molecule-1, *HLA-DR* human leukocyte antigen-DR, *GFAP* glial fibrillary acidic protein, *MAP2* microtubule-associated protein-2, *SYP* synaptophysin

^a *p* values shown are not corrected for false discovery rate (FDR)

Table 5:

Association of genetic loci with GCR, SYP, and MAP2

Genotype ^a	GCR			SYP			MAP2		
	Effect size	P value ^b	n	Effect size	P value ^b	n	Effect size	P value ^b	n
<i>IL6</i>	-0.43	0.303	148	1.122	0.346	8	-	0.947	88
						8	0.075		
<i>CCL3</i>	-	0.454	145	0.568	0.561	8	-	0.901	86
	0.250					6	0.116		
<i>HCP5</i>	-	0.800	148	-1.621	0.517	8	-	0.018	88
	0.214					8	5.451		
<i>CX3CR1</i>	-	0.275	148	0.562	0.571	8	0.873	0.354	88
	0.357					8			
<i>HFE</i>	-	0.004	148	0.766	0.517	8	0.273	0.809	88
	1.019					8			
<i>NFE2L2</i>	0.091	0.858	148	3.402	0.017	8	2.914	0.032	88
						8			
<i>CXCL12</i>	0.129	0.721	148	-1.148	0.253	8	-	0.453	88
						8	0.721		
<i>CCR2</i>	0.161	0.652	148	2.678	0.007	8	1.749	0.070	88
						8			
<i>BDNF</i>		0.365	148	1.023	0.306	8	-	0.644	88
	0.319					8	0.442		
<i>HEPH</i>	0.670	0.037	148	-1.601	0.084	8	-	0.399	88
						8	0.754		
<i>TNF</i>	0.483	0.198	146	0.895	0.428	8	1.289	0.228	88
						8			
<i>CD33</i>	-	0.056	147	1.163	0.263	8	1.255	0.215	87
	0.617					7			
<i>CCL2</i>	-	0.102	148	0.600	0.516	8	0.356	0.686	88
	0.508					8			
<i>MBL2</i>			148			8			88
						8			
A/O	0.422	0.027 ^c		1.025	0.118 ^c		-	0.310 ^c	
							0.239		
O/O	2.272			-6.423			-		
							6.009		
<i>APOE</i>			164			8			88
						8			
ε2	-	0.151 ^{c,d}		1.096	0.567 ^{c,d}	0	1.948	0.263 ^{c,d}	
	0.451								
ε4	0.515			-0.571			0.494		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

GCR global clinical rating, *SYP* synaptophysin, *MAP2* microtubule-associated protein-2

^aAll loci except *MBL* and *APOE* were run under a dominant acting genetic model

^bLog10 plasma HIV-1 RNA viral load and race/ethnicity included as covariates

^cOmnibus *p* value

^d ϵ 2 by ϵ 4 interaction not significant, so omitted from model

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 6:

Effect sizes and *p* values of GCR, MAP2, and SYP as outcomes

Outcome	Log10 plasma HIV-1 RNA viral load	<i>P</i> value	Race/ethnicity ^a	<i>P</i> value	SYP	<i>p</i> value	MAP2	<i>p</i> value
GCR	0.171	0.235	-0.862	0.314 ^b	-0.068	0.280	-	0.028
			-0.491				0.146	
			0.379					
MAP2	-0.056	0.812	-0.258	0.886 ^b	0.618	3.37×10 ⁻¹¹	-	-
			0.183					
			1.725					
SYP	-0.350	0.149	0.991	0.363 ^b	-	-	0.645	3.37×10 ⁻¹¹
			-0.362					
			-1.532					

GCR global clinical rating, MAP2 microtubule-associated protein-2, SYP synaptophysin

^aCategorized as African American, Hispanic, Asian/Native Alaskan with Caucasian as the reference group

^bOmnibus *p* value

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript